Remove Blood Pressure Remove Conditions Remove DEA Remove Patients
article thumbnail

What’s the deal with ketamine? Q&A on Special K

The Cannigma

2 3 As clinical trials around the world proceeded in the late 1960s and 1970s, patients began reporting difficulty tolerating ketamine’s unpleasant hallucinogenic and dissociative properties. It was also after the Vietnam War that widespread ketamine abuse would begin to show up as a party drug. 9 How is ketamine commonly used?

article thumbnail

AAFP ( American Academy of Family Physicians) Releases Marijuana, Cannabinoids Position Paper

Cannabis Law Report

Marijuana and related substance misuse are complex issues impacting family medicine, patient health, and public health. Barriers to facilitating both clinical and public health research regarding marijuana is detrimental to treating patients and the health of the public. Executive Summary. Relevant AAFP Policy. Call to Action.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

What is THC? Here’s everything you need to know

The Cannigma

Depending on the state you’re in, THC products may be legally accessible to any adult, and other states restrict access to medical patients only. Marijuana (defined in the US as any cannabis plant where THC>0.3%) is a schedule I drug according to the DEA and FDA. Other health concerns. How long does THC stay in your system?

THC 98
article thumbnail

How to access and assess ketamine therapy options

The Cannigma

Ketamine has a long safety record as an anesthetic since the 1980s, and it has also been successfully used “off-label” for over a decade to treat conditions such as anxiety, depression, OCD, and PTSD, among others. Patients may want to seek assistance from a certified professional prior to embarking on treatment.

Therapy 78
article thumbnail

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

Side effects were very prevalent in 79% of all patients taking a refined CBD product, some of which were severe like thrombocytopenia and transaminase elevations in the liver. Review: During an open-label trial of pure CBD with Lennox-Gastaut and Dravet patients, 79% of all patients reported side effects.